Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Innovations review observed that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://hermanny321vrk4.evawiki.com/user